Characteristics of the interactions of fibrinogen and soluble fibrin with cultured endothelial cells

1986 ◽  
pp. 203-210
Author(s):  
U. Delvos ◽  
K.T. Preissner ◽  
G. Müller-Berghaus
Diabetes ◽  
1995 ◽  
Vol 44 (11) ◽  
pp. 1323-1327 ◽  
Author(s):  
S. M. Baumgartner-Parzer ◽  
L. Wagner ◽  
M. Pettermann ◽  
J. Grillari ◽  
A. Gessl ◽  
...  

Diabetes ◽  
1997 ◽  
Vol 46 (9) ◽  
pp. 1481-1490 ◽  
Author(s):  
A. Bierhaus ◽  
S. Chevion ◽  
M. Chevion ◽  
M. Hofmann ◽  
P. Quehenberger ◽  
...  

2018 ◽  
Vol 64 (4) ◽  
pp. 504-507
Author(s):  
Vladimir Klimovich ◽  
Natalya Vartanyan ◽  
Anastasiya Stolbovaya ◽  
Lidiya Terekhina ◽  
Olga Shashkova ◽  
...  

During last years monoclonal antibodies (MAB) directed against vascular endothelium markers demonstrated their efficiency for visualization and targeted delivery of therapeutic drugs to tumors. Endoglin (CD105) which serves as a key element that determines endothelial cells quiescence or activation is one of such markers. Endoglin is highly expressed on the vascular endothelium of growing tumors. A first panel of MAB against endoglin in our country was produced at the hybridoma technology laboratory of RRC RST named after A.M. Granov. On the basis of these MAB ELISA was created allowing detection of endoglin in human plasma and other biological fluids. Several MAB had been shown to bind endoglin on the membrane of the cultured endothelial cells and to persist there for several hours. During the first 30 min after binding some of the immune complexes “endoglin-MAB” were internalized into the cytoplasm and were found included in the endosomes. In future these MAB can be used to create the reagents for the addressed delivery of isotope tags both on the membrane and into the cytoplasm of endothelial cells.


Circulation ◽  
1996 ◽  
Vol 94 (4) ◽  
pp. 727-733 ◽  
Author(s):  
Christo D. Venkov ◽  
Alan B. Rankin ◽  
Douglas E. Vaughan

1996 ◽  
Vol 50 (8) ◽  
pp. 396
Author(s):  
Sagripanti A ◽  
Morganti M ◽  
Carpi A ◽  
Barsotti M ◽  
Cupisti A ◽  
...  

1990 ◽  
Vol 101 (2) ◽  
pp. 237-239 ◽  
Author(s):  
Markus Hecker ◽  
Jane A. Mitchell ◽  
Tomasz A. Swierkosz ◽  
William C. Sessa ◽  
John R. Vane

Blood ◽  
1987 ◽  
Vol 69 (5) ◽  
pp. 1531-1534 ◽  
Author(s):  
LA Sporn ◽  
VJ Marder ◽  
DD Wagner

Abstract Large multimers of von Willebrand factor (vWf) are released from the Weibel-Palade bodies of cultured endothelial cells following treatment with a secretagogue (Sporn et al, Cell 46:185, 1986). These multimers were shown by immunofluorescent staining to bind more extensively to the extracellular matrix of human foreskin fibroblasts than constitutively secreted vWf, which is composed predominantly of dimeric molecules. Increased binding of A23187-released vWf was not due to another component present in the releasate, since releasate from which vWf was adsorbed, when added together with constitutively secreted vWf, did not promote binding. When iodinated plasma vWf was overlaid onto the fibroblasts, the large forms bound preferentially to the matrix. These results indicated that the enhanced binding of the vWf released from the Weibel-Palade bodies was likely due to its large multimeric size. It appears that multivalency is an important component of vWf interaction with the extracellular matrix, just as has been shown for vWf interaction with platelets. The pool of vWf contained within the Weibel-Palade bodies, therefore, is not only especially suited for platelet binding, but also for interaction with the extracellular matrix.


Sign in / Sign up

Export Citation Format

Share Document